Prostate-specific antigen screening in elderly men

Journal of the National Cancer Institute

Volumn 95, Issue 23, 2003, Pages 1792-1797

  Lu Yao, Grace ^a,c   Stukel, Therese A ^b   Yao, Siu Long ^c  

^a HealthStat   (United States)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC VALUE; GERIATRIC DISORDER; HEALTH BEHAVIOR; HEALTH STATUS; HEALTH SURVEY; HUMAN; INTERVIEW; MALE; OCCULT BLOOD; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RISK BENEFIT ANALYSIS;

EID: 0346888537     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg104     Document Type: Article

References (37)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Huntingt) 2000;14:267-72, 277-8, 280 passim.
3. Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002;52:8-22.
4. Fowler FJ Jr, Bin L, Collins MM, Roberts RG, Oesterling JE, Wasson JH, et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med 1998; 104:526-32.
5. Ferrini R, Woolf SH. American College of Preventive Medicine practice policy. Screening for prostate cancer in American men. Am J Prev Med 1998;15:81-4.
6. Poteat HT, Chen P, Loughlin KR, Winkelman JW, Allada R, Ma'luf N, et al. Appropriateness of prostate-specific antigen testing. Am J Clin Pathol 2000;113:421-8.
7. Richter F, Dudley AW Jr, Irwin RJ Jr, Sadeghi-Nejad H. Are we ordering too many PSA tests? Prostate cancer diagnosis and PSA screening patterns for a single Veterans Affairs Medical Center. J Cancer Educ 2001; 16:38-41.
8. Carter HB, Landis PK, Metter EJ, Fleisher LA, Pearson JD. Prostate-specific antigen testing of older men. J Natl Cancer Inst 1999; 91:1733-7.
9. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-80.
10. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians. Ann Intern Med 1997;126:468-79.
11. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. JAMA 1994;272:773-80.
12. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA 1993;269: 2650-8.
13. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden [published erratum appears in JAMA 1997;278: 206]. JAMA 1997;277:467-71.
14. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusenmo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267:2191-6.
15. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-8.
16. Merrill RM. Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah. Prev Med 2001;33:646-52.
17. Etzioni R, Berry KM, Legler JM, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of Medicare claims from 1991-1998. Urology 2002;59:251-5.
18. National Center for Health Statistics. Data file documentation, National Health Interview Survey, 2000 [machine readable data file and documentation]. Hyattsville (MD): National Center for Health Statistics; 2001. Available at: http://www.cdc.gov/nchs/nhis.htm#2000_NHIS. [Last accessed: October 24, 2003.]
19. Hiatt RA, Klabunde C, Breen N, Swan J, Ballard-Barbash R. Cancer screening practices from National Health Interview Surveys: past, present, and future. J Natl Cancer Inst 2002;94:1837-46.
20. Breen N, Wagener DK, Brown ML, Davis WW, Ballard-Barbash R. Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. J Natl Cancer Inst 2001;93:1704-13.
21. Brown ML, Potosky AL, Thompson GB, Kessler LG. The knowledge and use of screening tests for colorectal and prostate cancer: data from the 1987 National Health Interview Survey. Prev Med 1990;19:562-74.
22. Sarndal C, Swensson B, Wretman JH. Model assisted survey sampling. 4th ed. New York (NY): Springer Verlag; 1992.
23. Stata software, version 7.0. College Station (TX): Stata Corporation; 2001.
24. Cowen ME, Kattan MW, Miles BJ. A national survey of attitudes regarding participation in prostate carcinoma testing. Cancer 1996;78:1952-7.
25. Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995;274:1445-9.
26. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 2003; 97:1528-40.
27. Perkins JJ, Sanson-Fisher RW, Clarke SJ, Youman P. An exploration of screening practices for prostate cancer and the associated community expenditure. Br J Urol 1998;82: 524-9.
28. Slevin TJ, Donnelly N, Clarkson JP, English DR, Ward JE. Prostate cancer testing: behaviour, motivation and attitudes among Western Australian men. Med J Aust 1999;171: 185-8.
29. Carter F, Graham E, Pal N, Gonzalez E, Roetzheim R. Prostate cancer screening in primary care. South Med J 1999;92:300-4.
30. Steele CB, Miller DS, Maylahn C, Uhler RJ, Baker CT. Knowledge, attitudes, and screening practices among older men regarding prostate cancer. Am J Public Health 2000;90: 1595-600.
31. Federman DG, Goyal S, Kamina A, Peduzzi P, Concato J. Informed consent for PSA screening: does it happen? Eff Clin Pract 1999;2:152-7.
32. Diefenbach PN, Ganz PA, Pawlow AJ, Guthrie D. Screening by the prostate-specific antigen test: what do the patients know? J Cancer Educ 1996;11:39-44.
33. Minino AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: final data for 2000. Natl Vital Stat Rep 2002;50:1-119.
34. Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst 2002;94:958-60.
35. Lofters A, Juffs HG, Pond GR, Tannock IF. "PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer. J Urol 2002;168:2516-20.
36. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
37. U.S. Census Bureau. Current population survey: poverty 2000. Washington (DC): U.S. Department of Commerce; 2001. Available at: http://www.census.gov/hhes/poverty/povdef. html. [Last accessed: October 24, 2003.]